IREMMI—Coverage of TCT Connect 2020 | SCAI

In the structural heart disease space, IREMMI evaluated the safety and efficacy outcomes of MitraClip to treat patients with acute mitral regurgitation (MR) following acute myocardial infarction (AMI) with and without cardiogenic shock (CS). The findings of the prospective registry from 18 centers across eight countries showed that CS does not appear to have an impact on the results of mitral valve repair with MitraClip in patients with acute MR after AMI. After a median follow-up of seven months (range 0-81 months), overall mortality did not differ between groups (16% CS vs. 9.3% non-CS, p=0.377), and the combined event rate (mortality/rehospitalization) due to heart failure was similar (28% CS vs. 25.6% non-CS, p=0.793). Mitral valve repair using MitraClip may, therefore, be a safe and effective therapy for patients with post-MI severe acute mitral regurgitation who are deemed too high risk for conventional surgery, regardless of the presence or absence of cardiogenic shock. 

All Editors: David A. Cox, MD, MSCAI, Allison G. Dupont, MD, FSCAI, Kirk N. Garratt, MD, MSc, MSCAI, Cindy L. Grines, MD, MSCAI, Andrew J. Klein, MD, FSCAI, and Jordan Safirstein, MD, FSCAI. 

Other Specialist Resources for Structural Heart Disease

Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations.